8-K: Grace Therapeutics Receives FDA Complete Response Letter for GTx-104

Grace Therapeutics announced the FDA issued a Complete Response Letter for its New Drug Application for GTx-104, citing CMC and non-clinical issues.

Summary

• Grace Therapeutics received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for GTx-104, a novel injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
• The FDA's CRL cited outstanding items related to Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical information, specifically concerning leachables data for product packaging, non-clinical product toxicology risk assessments, and manufacturing deficiencies at their contract manufacturing organization.
• The FDA did not request additional clinical data.
• Grace Therapeutics intends to resubmit the application after addressing the cited issues and plans to request a Type A meeting with the FDA to clarify the path forward.
• The STRIVE-ON trial, which supported the NDA, met its primary endpoint, showing a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% vs. 35%).
• Patients on GTx-104 also showed a higher relative dose intensity (54% vs. 8%) and more favorable functional outcomes at 90 days (29% more patients).
• Fewer ICU readmissions, ICU days, and ventilator days were observed for patients on GTx-104.
• Adverse events were comparable between GTx-104 and oral nimodipine, with no new safety issues identified.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the FDA's Complete Response Letter, despite the company's confidence in addressing the issues and the positive clinical trial results.

Positives

• The FDA did not request additional clinical data, suggesting the clinical efficacy and safety profile demonstrated in the STRIVE-ON trial is considered sufficient.
• The STRIVE-ON trial met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine.
• GTx-104 showed improved relative dose intensity (54% vs. 8%) and more favorable functional outcomes at 90 days (29% more patients) compared to oral nimodipine.
• Patients treated with GTx-104 experienced fewer ICU readmissions, ICU days, and ventilator days.
• Adverse events were comparable between GTx-104 and oral nimodipine, with no new safety concerns identified.
• GTx-104 has been granted Orphan Drug Designation by the FDA, providing seven years of marketing exclusivity in the U.S. upon approval.

Negatives

• The FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of GTx-104.
• The CRL cited outstanding items in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application.
• Specific CMC issues include leachables data for product packaging and product manufacturing deficiencies at the contract manufacturing organization.
• Non-clinical issues relate to product toxicology risk assessments.
• There were eight deaths in the GTx-104 arm of the STRIVE-ON trial compared to four deaths in the oral nimodipine arm, although no deaths were determined to be related to the drug.

Risks

• Potential delays in resubmission and subsequent FDA review of the NDA for GTx-104.
• The success of addressing the CMC and non-clinical issues cited by the FDA.
• Changes to regulatory requirements or pathways for drug approval.
• The ability to protect intellectual property for drug candidates.
• Legislative, regulatory, political, and economic developments that could impact the company or its products.

Future Outlook

Grace Therapeutics intends to resubmit its NDA for GTx-104 following the resolution of the CMC and non-clinical issues identified by the FDA. The company plans to request a Type A meeting with the FDA to clarify the path forward and determine appropriate next steps for resubmission.

Management Comments

• "Potential FDA approval of our NDA for GTx-104 for the treatment of aSAH would represent the first meaningful innovation in the standard of care for these patients in more than 40 years," said Prashant Kohli, Chief Executive Officer of Grace Therapeutics.
• "We are confident in the robust data package supporting our NDA submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission."

Industry Context

StockSavvy.ai notes that the FDA's Complete Response Letter for GTx-104 highlights the rigorous scrutiny applied to new drug applications, particularly concerning manufacturing and non-clinical data. While the clinical data appears positive, the CMC and manufacturing aspects are critical hurdles for biopharmaceutical companies seeking market approval. The company's plan to address these issues and seek further FDA guidance is a standard, albeit challenging, path forward in the drug development lifecycle.

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to the delay in drug approval and the uncertainty surrounding the resubmission process.
• Patients: Continued delay in access to a potentially innovative treatment for aSAH.
• Employees: Potential impact on morale and future company growth prospects due to regulatory setback.

Next Steps

• Address the outstanding items related to Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical information cited in the CRL.
• Request a Type A meeting with the FDA to clarify the path forward and determine appropriate next steps for resubmission.
• Resubmit the NDA for GTx-104 after addressing the cited issues.

Key Dates

Recommendation

The company has received a setback with the FDA's Complete Response Letter, introducing uncertainty and delaying the potential commercialization of GTx-104. However, the clinical data remains promising, and the issues cited are related to CMC and non-clinical aspects, which the company believes are addressable. A 'hold' recommendation is appropriate given the mixed signals: a regulatory hurdle but underlying positive clinical data and a clear path to resubmission.

Keywords

Grace Therapeutics, GTx-104, aSAH, Complete Response Letter, FDA, NDA, nimodipine, biopharmaceutical